You just read:

Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar

News provided by

Sirnaomics, Inc.

Nov 07, 2016, 08:58 ET